Success Metrics

Active Trials

4(80%)

Phase Distribution

Ph phase_1

40%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

2(50.0%)

Phase 2Efficacy & side effects

2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Other(1)

Detailed Status

Recruiting3

unknown1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 12 (50.0%)

Phase 22 (50.0%)

Trials by Status

unknown120%

recruiting360%

active_not_recruiting120%

Recent Activity

4 active trials

Showing 5 of 5

active_not_recruitingphase_1

HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

NCT03354390

recruitingphase_2

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

NCT06412497

Clinical Trials (5)

Showing 5 of 5 trials

NCT03354390Phase 1

HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

Active Not Recruiting

NCT06872333Phase 2

Allo HSCT for High Risk Hemoglobinopathies

Recruiting

NCT05389514

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

Unknown

NCT06090864Phase 1

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

Recruiting

NCT06412497Phase 2

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Recruiting

All 5 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 5